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Objective. To investigate WWOX messenger RNA (mRNA) transcriptional levels in giant cell lesions (GCLs) of the jaws and
associate its expression with clinical parameters.
Study design. In this pilot study, quantitative reverse-transcription polymerase chain reaction was performed to analyze
WWOX expression in 6 central giant cell lesions (CGCLs) (including 2 aggressive), 5 peripheral giant cell lesions (PGCLs) and
1 cherubism sample. Immunohistochemistry was performed to confirm the localization of the Wwox protein.
Results. CGCL and PGCL showed an overall increased expression of WWOX, as did the cherubism case, but no differences
were observed among the groups. Wwox was localized almost entirely to the cytoplasm of multinucleated giant cells, as well
as in a few mononuclear cells. CGCL and PGCL showed higher expression of the WWOX mRNA than peripheral blood
mononuclear cells. The 2 aggressive CGCL samples exhibited decreased WWOX expression.
Conclusions. These results showed increased expression of WWOX mainly in non-aggressive GCLs of the jaws. (Oral Surg
Oral Med Oral Pathol Oral Radiol 2013;116:210-213)Oral lesions with multinucleated giant cells comprise
a group with diverse pathological alterations. Central
giant cell lesions (CGCLs) occur mainly in the mandible
of individuals between 10 and 25 years of age. Despite
being regarded as a reactive intra-osseous lesion of
unknown etiology,1 there is not enough evidence to rule
out a neoplastic origin. Radiographically, they may
present as small unilocular or large multilocular lesions,
causing tooth displacement and cortical perforation.2
Peripheral giant cell lesions (PGCLs) are reactive exo-
phytic soft tissue lesions, most likely originating from
periodontal ligament or mucoperiosteum. These are
related to local irritating factors, such as plaque, calculus,
and unstable dental prostheses.3 CGCLs and PGCLs
show multinucleated osteoclast-like giant cells inter-
mingled with oval to spindle-shaped mononuclear cells.4
The giant cells of both lesions are Ki-67 negative.
Contrarily, mononuclear cells of both entities stain
positive for Ki-67, therefore corresponding to the
proliferating cells of the lesions. On the basis of these
observations, it seems that the giant cells of PGCL and
CGCL are formed by the cytoplasmic fusion of mono-
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210Cherubism is an autosomal dominant disease that is
characterized by cortical expansion and replacement of
bone of the jaws with ﬁbrous tissue8 histologically in-
distinguishable from CGCL.9 Bone expansion is usually
detected in early childhood and shows progressive
growth until puberty.10 The SH3BP2 gene, localized
to chromosome 4p.16, has been associated with cherub-
ism, with most mutations occurring in exon 9.11 SH3BP2
encodes a cytoplasmic adapter protein that forms
complexes with other proteins, culminating in the tran-
scription of genes such as NFATc1 that, in turn, is asso-
ciated with osteoclastogenesis and bone resorption.12,13
The WWOX gene was cloned in 2000 and spans the
second most common chromosomal fragile site,
FRA16D.14,15 WWOX is a proapoptotic gene, and loss
of or reduced Wwox expression has been reported in
many tumor types.14-21 The most frequent alterations in
this region are loss of heterozygosity, deletions and
translocations.15,22 The Wwox protein interacts with
p73, a member of the p53 family, and induces cell
apoptosis.22 It also enhances tumor necrosis factor
(TNF), causing down-regulation of the apoptosis
inhibitors Bcl-2 and Bcl-x.23 Overexpression of Wwox
in cell lines results in caspase-mediated apoptosis.24,25
In a recent study, our group demonstrated an in-
creased expression of apoptosis-related genes in CGCL
and PGCL.26 Considering that WWOX is a proapoptoticStatement of Clinical Relevance
WWOX is a proapoptotic gene and its expression was
shown to be increased mainly in the non-aggressive
giant cell lesions in this pilot study.
Table I. Clinical data for the giant cell lesion samples
Diagnosis Age (y) Sex Location Aggressiveness*
CGCL
#1 12 Female Mandible No
#2 41 Female Mandible No
#3 11 Male Mandible Yes
#4 46 Male Mandible Yes
#5 19 Male Mandible No
#6 NA Male Mandible NA
PGCL
#1 47 Male Mandible e
#2 22 Female Maxillary gingiva e
#3 24 Male Mandible e
#4 50 Female Maxillary gingiva e
#5 52 Female Maxillary gingiva e
CHERUBISM
#1 12 Female Mandible e
CGCL, central giant cell lesion; PGCL, peripheral giant cell lesion;
NA, not available.
*The lesions were considered aggressive if they were larger than 4 cm
in size and presented damaged or expanded cortical bone and tooth
displacement, as described by Chuong et al., 1986.27 PGCL #2
recurred 2 years after surgical excision.
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in these lesions.27
MATERIALS AND METHODS
Tissue samples
A total of 12 fresh tumor samples comprising 6 CGCL,
5 PGCL and 1 case of cherubism were included in this
study (Table I). The cherubism case was previously
reported.28 This patient harbored a germline mutation in
exon 4 and presented 2 multilocular radiolucent lesions
associated with tooth displacement. CGCL samples
were considered aggressive when lesions were larger
than 4 cm in size and presented cortical bone destruc-
tion or expanding and tooth displacement, as described
by Chuong et al., 1986.27 The local ethics committee
approved the study (protocol 365/07).
Quantitative reverse-transcription polymerase
chain reaction (qRT-PCR)
Total RNA was isolated using Tri-Phasis Reagent
(BioAgency, São Paulo, Brazil) and treated with DNase
(Invitrogen Life Technologies, Carlsbad, CA, USA).
Complementary DNA (cDNA) was synthesized with
Superscript First-Strand Synthesis System Kit (Invi-
trogen Life Technologies) according to the manufac-
turer’s instructions. For quantitative PCR analyses,
WWOX cDNA transcripts were detected as described
previously.18 Brieﬂy, the reactions were performed in
duplicates on a StepOne thermocycler (Applied Bio-
systems, Foster City, CA, USA). The cycling parameters
were 10 min at 95 C followed by 40 cycles at 95 C for
15 s and 57 C for 1 min, and a melting curve analysis
was performed afterward. WWOX expression was
normalized to actin (internal control). The average
threshold cycle (Ct) for 2 replicates per sample was used
to calculate DCt. Relative quantiﬁcation (RQ) of WWOX
cDNA was calculated with the 2DDCt method. The
2DDCt or comparative Ct method is a quantitation
approach used to determine the relative target quantity in
samples. It compares the Ct values of the samples of
interest with a calibrator sample. The Ct values of both,
the calibrator and the samples of interest, are normalized
to an appropriate endogenous housekeeping gene (actin).
Data was presented as the relative quantity of target gene
(WWOX) normalized to endogenous actin and relative to
a calibrator sample (reference). Normal oral mucosa
samples were included as calibrators. cDNA from
peripheral blood mononuclear cells (PBMC) was used as
the control because the giant cells from the lesions that
were included in the study are believed to have origi-
nated from cytoplasmic fusion of mononucleated
cells.5-7 Blood samples were collected from healthy
volunteers and normal oral mucosa samples were ob-
tained from healthy volunteers during 3rd unerupted
molar extractions with no clinical signs of inﬂammation.Immunohistochemistry
Immunohistochemistry analysis for the localization of the
Wwox protein was performed using a polyclonal antibody
(Abcam, Cambridge, MA, USA). Brieﬂy, the process of
deparafﬁnization, hydration, and antigen retrieval was
performed by immersing the slides in Trilogy solution
(Cell Marque, Rocklin, CA, USA), heated at 98 C in
a steamer for 20 min and incubated with the primary
antibody diluted at 1:15 for 30 min at room temperature.
After washing in TriseHCl buffer, the sections were
incubated for 30 min at room temperature with
EnVision þ Dual Link System-HRP (Dako, Carpinteria,
CA, USA). The reactions were detected by applying the
3,30-diaminobenzidine chromogen (Dako, Carpinteria,
CA, USA) to the buffer solution. The sections were
counterstained with hematoxylin and mounted in Entellan
(Merck KGaA, Darmstadt, Germany). All immunostain-
ing procedures were performed manually, and a normal
oral mucosa specimen was used as the positive control.
The negative control was prepared with omission of the
primary antibody, resulting in no detectable staining.
The immunolocalization of the protein was evaluated in
the histological sections representative of whole tumors,
considering the cytoplasmic staining in both giant and
mononuclear cells under high-power magniﬁcation
(400), regardless of staining intensity.
Statistical analysis
Statistical signiﬁcance was analyzed with the
ManneWhitney test. P< .05 was considered signiﬁcant.
RESULTS
qRT-PCR ampliﬁcation was performed to determine
WWOX mRNA expression levels in giant cell lesions
Fig. 1. WWOX expression in CGCL (central giant cell lesion), PGCL (peripheral giant cell lesion), cherubism and PBMC
(peripheral blood mononuclear cell). A: WWOX mRNA expression. The RQ (relative quantiﬁcation) represents the relative
expression level (fold change). The log of the RQ values was used to plot the relative expression level of WWOX in the GCLs and
PBMC samples, in relation to the calibrator. The x-axis represents normal oral mucosa used as the calibrator sample. CGCL #3 and
#4 were aggressive lesions. B and C: The Wwox protein localized mainly in the cytoplasm of multinucleated giant cells of 2
different PGCLs (original magniﬁcation 400).
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and PGCL showed an overall increased expression of
WWOX, all PBMC control samples showed a decreased
expression compared with the calibrator. The single
case of cherubism also showed higher expression of
WWOX compared with normal mucosa. Both the CGCL
(P ¼ .01) and PGCL samples (P ¼ .01) showed
statistically signiﬁcant higher expression of WWOX
mRNA than the PBMC samples. However, there was
no difference in WWOX expression between CGCL and
PGCL. In addition, both CGCL samples that expressed
less WWOX than the calibrator also exhibited aggres-
sive clinical behavior (samples #3 and #4). Further-
more, the relative level of WWOX mRNA was not
associated with sex, age, or lesion site.
Wwox protein was detected almost exclusively in the
cytoplasm of multinucleated giant cells and in a few
isolated mononuclear cells (Figure 1B and C).
DISCUSSION
In the present study, GCLs demonstrated an overall
increased level of WWOX expression compared with
PBMC, and immunohistochemistry analysis conﬁrmed
that the Wwox protein is expressed almost exclusively
by the giant cells.
WWOX has an important role in apoptosis as previ-
ously demonstrated.22,24,25 In a recent study wedemonstrated an increased apoptotic index of CGCL and
PGCL and showed that the giant cells were the main
source of this apoptotic event.26 Our current results show
that the giant cells express more WWOX than the
mononuclear cells. Mononuclear cells, in turn, were
previously suggested to be the proliferating cells in these
lesions, and so we did not expect them to express high
levels of apoptotic proteins. Taken together, our data
suggest a possible involvement of WWOX in apoptosis
of giant cells in these GCLs, and this event may be
associated with clinical behaviors of these lesions.
Interestingly, both CGCL samples that exhibited
decreased WWOX mRNA expression were aggressive
lesions associated with damaged or expanded cortical
bone and tooth displacement. These 2 lesions also did
not express the Wwox protein based on the immuno-
histochemistry analysis. In aggressive bone tumors such
as osteosarcomas, WWOX expression has been previ-
ously shown to be reduced or absent.29,30 Our results
strengthen the hypothesis that aggressive CGCL may
represent a neoplastic subset of this group of lesions.
Because this pilot study included a relatively small
number of cases, further studies on larger series of
aggressive CGCL cases as well as recurrent PGCL
cases would provide more conclusive evidence to
determine if decreased WWOX expression is associated
with more aggressive clinical behavior. Because
OOOO ORIGINAL ARTICLE
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the association between decreased WWOX expression
and an aggressive behavior remains to be established as
a driver or a passenger event.
In conclusion, our pilot study shows a notably high
level of WWOX expression in non-aggressive GCLs of
the jaws. In light of our ﬁndings, we suggest that
additional translational studies need to be conducted in
order to further clarify the role of WWOX in the clinical
behaviors of these lesions.
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